Quality Assessment: Consistent Financial Strength and Operational Excellence
Glenmark Pharma’s quality rating has been bolstered by its sustained financial performance and operational efficiency. The company reported positive results for three consecutive quarters, with the latest six-month PAT soaring to ₹1,133.97 crores, marking a remarkable growth of 103.40%. Net sales for the nine months ended FY25-26 reached ₹13,718.08 crores, up 36.13% year-on-year, signalling strong top-line momentum.
Return on Capital Employed (ROCE) stands at an impressive 40.16% for the half-year period, highlighting efficient utilisation of capital. Additionally, the Return on Equity (ROE) is a healthy 26.9%, reflecting strong profitability relative to shareholder equity. The company’s low Debt to EBITDA ratio of 0.13 times further emphasises its solid balance sheet and ability to service debt comfortably, reducing financial risk.
These quality parameters place Glenmark among the top 1% of companies rated by MarketsMojo across a universe of over 4,000 stocks, underscoring its operational robustness and financial discipline.
Valuation: Attractive Pricing Relative to Peers and Historical Levels
Glenmark’s valuation has become increasingly compelling, supporting the upgrade to a Buy rating. The stock trades at a Price to Book Value of 6.1, which, while elevated, is considered attractive given the company’s strong earnings growth and return ratios. The Price/Earnings to Growth (PEG) ratio is a low 0.2, indicating that the stock’s price growth is undervalued relative to its earnings growth potential.
Over the past year, the stock has delivered a 4.74% return, modest but positive, while profits have surged by 125.6%. This disconnect suggests the market has yet to fully price in Glenmark’s earnings acceleration. Furthermore, the stock is trading at a discount compared to its peers’ average historical valuations, offering investors a favourable entry point.
Institutional investors hold a significant 39.54% stake in the company, reflecting confidence from sophisticated market participants who typically conduct rigorous fundamental analysis before committing capital.
Under the radar no more! This Large Cap from Cement is emerging from turnaround with solid fundamentals intact. Discover it while it's still relatively hidden!
- - Hidden turnaround gem
- - Solid fundamentals confirmed
- - Large Cap opportunity
Financial Trend: Sustained Growth and Profitability Momentum
The financial trend for Glenmark Pharmaceuticals has been decidedly positive, with the company demonstrating consistent growth in key metrics. The latest quarterly results for Q4 FY25-26 confirm the continuation of this trend, with strong revenue and profit growth.
Year-to-date, the stock has returned 11.10%, significantly outperforming the Sensex, which has declined by 8.88% over the same period. Over longer horizons, Glenmark’s returns have been exceptional: 183.27% over three years and 282.34% over five years, dwarfing the Sensex’s respective returns of 17.37% and 47.48%. This consistent outperformance highlights the company’s ability to generate shareholder value over time.
Profit growth has been particularly impressive, with a 125.6% increase over the past year, signalling strong operational leverage and effective cost management. The company’s ability to sustain such growth while maintaining low leverage is a key factor in the upgrade.
Technicals: Shift to Mildly Bullish Momentum Supports Positive Outlook
The upgrade in Glenmark’s rating is also driven by a notable improvement in technical indicators. The technical trend has shifted from mildly bearish to mildly bullish, reflecting increased buying interest and positive price momentum.
Key technical signals include a bullish daily moving average and Bollinger Bands indicating strength on both weekly and monthly charts. The MACD is bullish on the monthly timeframe, although mildly bearish on the weekly, suggesting a longer-term positive trend with some short-term consolidation.
Other indicators such as the Relative Strength Index (RSI) show no extreme signals, implying the stock is not overbought or oversold. The KST oscillator remains mildly bearish on both weekly and monthly charts, while Dow Theory and On-Balance Volume (OBV) show no strong trends weekly but mildly bearish monthly. Overall, the technical picture supports a cautiously optimistic outlook.
On 30 Jul 2026, Glenmark’s stock price closed at ₹2,261.95, up 3.53% from the previous close of ₹2,184.90. The stock traded within a range of ₹2,188.70 to ₹2,266.60, remaining comfortably above its 52-week low of ₹1,794.00 and approaching its 52-week high of ₹2,471.05.
Curious about Glenmark Pharmaceuticals Ltd. from Pharmaceuticals & Biotechnology? Get the complete picture with our detailed research report covering fundamentals, technicals, peer analysis, and everything you need to decide!
- - Detailed research coverage
- - Technical + fundamental view
- - Decision-ready insights
Comparative Performance and Market Positioning
Glenmark’s stock has consistently outperformed broader market indices and sector peers. Over the past year, it has generated a 4.74% return compared to the Sensex’s negative 4.53%. Over three and five years, the stock’s returns of 183.27% and 282.34% respectively far exceed the Sensex’s 17.37% and 47.48%, demonstrating sustained superior performance.
The company’s mid-cap status places it in a dynamic growth segment of the market, with ample room for expansion. Its strong fundamentals, combined with improving technicals, make it a compelling choice for investors seeking exposure to the Pharmaceuticals & Biotechnology sector.
Institutional ownership of nearly 40% further validates the stock’s investment appeal, as these investors typically possess the expertise and resources to conduct thorough fundamental analysis.
Conclusion: Upgrade Reflects Balanced Strength Across Key Parameters
The upgrade of Glenmark Pharmaceuticals Ltd. from Hold to Buy by MarketsMojo is a reflection of its improved quality metrics, attractive valuation, positive financial trends, and a shift to a mildly bullish technical stance. The company’s strong earnings growth, robust return ratios, low leverage, and consistent outperformance relative to the Sensex and peers provide a solid foundation for this positive rating change.
While some technical indicators remain cautiously mixed, the overall momentum supports a constructive outlook. Investors looking for a fundamentally sound and technically improving stock in the Pharmaceuticals & Biotechnology sector would find Glenmark an appealing candidate at current levels.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
